2
|
Zhang ML, Chen WS, Han B. [Evaluation of the efficacy of cyclosporin A combined with recombined human thrombopoietin for treating patients with non-severe aplastic anemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2020; 41:637-642. [PMID: 32942816 PMCID: PMC7525171 DOI: 10.3760/cma.j.issn.0253-2727.2020.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Subscribe] [Scholar Register] [Received: 03/08/2020] [Indexed: 11/05/2022]
Abstract
Objectives: To compare the efficacy of cyclosporin A (CsA) alone and CsA combined with recombined human thrombopoietin (rhTPO) in patients with non-severe aplastic anemia (NSAA) . Methods: Data from 83 patients with NSAA between August 2014 and February 2019 were collected retrospectively. The study population included 35 men and 48 women, with a median age of 45 years (14-85 years) . Among them, 57 had been treated with CsA + rhTPO, TPO was administered at 15 000 U QD for 7 days, once a month for 3 months, and the other 26 patients with compatible baseline characters were treated with CsA alone. All the enrolled patients had been treated with CsA for at least 6 months and were followed up for at least 1 year. The efficacy and outcome were compared between the two groups. Results: Total 23 men and 34 women, with a median age of 46 years (14-85 years) were treated with CsA + rhTPO. The median duration of CsA treatment was 17 (8-28) months, and the patients were followed up for a median of 27 (12-45) months. Total 12 men and 14 women, with a median age of 40 years (20-64) were treated with CsA alone. The median duration of CsA treatment was 19 months (9-30 months) , and the median follow-up duration was 29 months (16-66 months) . There was no significant difference in the baseline characteristics of the two groups (P>0.05) . There was no significant difference in the CR and OR rates of the two groups at 1, 3, 6, 12, and 24 months of treatment (P>0.05) . The change in the platelet level for the CsA + rhTPO treated group after 1 month[8 (-12-86) ×10(9)/L vs. 3 (16-57) ×10(9)/L, P=0.029) , 3 months[24 (-6-102) ×10(9)/L vs. 7 (-9-76) ×10(9)/L, P=0.006], and 6 months[33.5 (-4-123) ×10(9)/L vs. 12.5 (-14-109) ×10(9)/L, P=0.048] of treatment was higher than that in the CsA alone group, while no significant difference was found between the two groups at other time points. There was no significant difference in the change in the megakaryocyte level between the two groups[3 (0-4) vs. 2 (0-5) , z=-0.868, P=0.385] after 6 months of treatment. Apart from 10.5% (6/57) of the patients in the CsA + rhTPO treated group who reported soreness at the injection site, there was no other significant difference between the two groups in terms of adverse effects. During the follow-up period, there were two cases of increasing paroxysmal nocturnal hemoglobinuria clone to over 10%, one in the CsA + rhTPO treated group, the other in the CsA alone group; and there was one case of progression to SAA in the CsA + rhTPO treated group; while no case of death or thromboembolic event (TEE) , fibrosis or reticulin proliferation, progression to myelodysplastic syndrome (MDS) , or acute myeloid leukemia was observed in either group. There was one case of progression to SAA in the CsA + rhTPO treated group but none in the CsA alone group. Conclusion: Compared to CsA alone, CsA + rhTPO treatment can accelerate the recovery of the platelet level with acceptable adverse effects.
Collapse
Affiliation(s)
- M L Zhang
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences, Beijing 100730, China
| | - W S Chen
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences, Beijing 100730, China
| | - B Han
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences, Beijing 100730, China
| |
Collapse
|
3
|
杨 博, 罗 庆, 康 权, 肖 程, 王 健, 李 志, 龚 梦, 毕 杨. [Tumor necrosis factor-α and transforming growth factor-β 1 balance liver stem cell differentiation in cholestatic cirrhosis]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2018; 38:375-383. [PMID: 29735435 PMCID: PMC6765666 DOI: 10.3969/j.issn.1673-4254.2018.04.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Indexed: 06/08/2023]
Abstract
OBJECTIVE To investigate the changes of tumor necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) in mice with cholestatic cirrhosis and their role in regulating the balance of liver stem cell differentiation. METHODS Balb/c mice were subjected to bile duct ligation (BDL), and serum biochemical parameters were measured and hepatic histopathology was observed using HE staining to evaluate the modeling of cholestatic cirrhosis. Immunohistochemistry and Western blotting were used to detect the changes of TNF-α and TGF-β1 in the mice after modeling. Mouse embryonic hepatic stem cells (HP14-19) were treated with different concentrations of TNF-α and TGF-β1, and the cell differentiation was assessed using Western blotting, real-time PCR, and PAS staining. RESULTS The mice receiving BDL showed significantly increased blood biochemical parameters (P<0.05), and HE staining revealed obviously increased collagen fibers in the liver with significantly increased expressions of TNF-α and TGF-β1 (P<0.05). In HP14-19 cells, induction with TNF-α and TGF-β1 for 3 days did not cause significant changes in cell differentiation, but induction for 5 days resulted in significantly increases intensity of PAS staining in the cells. The cells induced with 20, 40, and 80 ng/mL TNF-α for 5 days exhibited a significantly stronger expression of cytokeratin 18 than cytokeratin 19 (P<0.05), while induction with 20, 40, and 80 ng/mL TGF-β1 produced opposite changes in cytokeratin 18 and cytokeratin 19 expressions. Further induction of the cells with TNF-α and TGF-β1 for 10 days, did not alter the expression patterns of cytokeratin 18 and cytokeratin 19 observed on day 5, but their protein expression levels and PAS staining intensity of the cells were enhanced and their mRNA expressions became lowered. CONCLUSION Common bile duct ligation can induce conditions simulating cholestatic cirrhosis in mice. TNF-α and TGF-β1 are elevated in cholestatic cirrhosis and play opposite roles in regulating the differentiation balance of liver stem cells: the former promotes the differentiation of liver stem cells into hepatocytes, while the latter promotes the cell differentiation into colangiocytes.
Collapse
Affiliation(s)
- 博 杨
- 重庆医科大学附属儿童医院 肝胆外科,重庆 400014Department of Hepatology, Children's Hospital of Chongqing Medical University, Chongqing 400014, China
- 重庆医科大学附属儿童医院 儿科研究所干细胞实验室//儿童发育疾病研究所教育部重点实验室//儿童发育重大疾病国家国际科技合作基地//儿科学重庆市重点实验室,重庆 400014Laboratory of Stem Cell Biology and Therapy, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - 庆 罗
- 重庆医科大学附属儿童医院 儿科研究所干细胞实验室//儿童发育疾病研究所教育部重点实验室//儿童发育重大疾病国家国际科技合作基地//儿科学重庆市重点实验室,重庆 400014Laboratory of Stem Cell Biology and Therapy, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - 权 康
- 重庆医科大学附属儿童医院 肝胆外科,重庆 400014Department of Hepatology, Children's Hospital of Chongqing Medical University, Chongqing 400014, China
- 重庆医科大学附属儿童医院 儿科研究所干细胞实验室//儿童发育疾病研究所教育部重点实验室//儿童发育重大疾病国家国际科技合作基地//儿科学重庆市重点实验室,重庆 400014Laboratory of Stem Cell Biology and Therapy, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - 程 肖
- 重庆医科大学附属儿童医院 儿科研究所干细胞实验室//儿童发育疾病研究所教育部重点实验室//儿童发育重大疾病国家国际科技合作基地//儿科学重庆市重点实验室,重庆 400014Laboratory of Stem Cell Biology and Therapy, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - 健 王
- 重庆医科大学附属儿童医院 肝胆外科,重庆 400014Department of Hepatology, Children's Hospital of Chongqing Medical University, Chongqing 400014, China
- 重庆医科大学附属儿童医院 儿科研究所干细胞实验室//儿童发育疾病研究所教育部重点实验室//儿童发育重大疾病国家国际科技合作基地//儿科学重庆市重点实验室,重庆 400014Laboratory of Stem Cell Biology and Therapy, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - 志鹏 李
- 重庆医科大学附属儿童医院 肝胆外科,重庆 400014Department of Hepatology, Children's Hospital of Chongqing Medical University, Chongqing 400014, China
- 重庆医科大学附属儿童医院 儿科研究所干细胞实验室//儿童发育疾病研究所教育部重点实验室//儿童发育重大疾病国家国际科技合作基地//儿科学重庆市重点实验室,重庆 400014Laboratory of Stem Cell Biology and Therapy, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - 梦嘉 龚
- 重庆医科大学附属儿童医院 儿科研究所干细胞实验室//儿童发育疾病研究所教育部重点实验室//儿童发育重大疾病国家国际科技合作基地//儿科学重庆市重点实验室,重庆 400014Laboratory of Stem Cell Biology and Therapy, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - 杨 毕
- 重庆医科大学附属儿童医院 儿科研究所干细胞实验室//儿童发育疾病研究所教育部重点实验室//儿童发育重大疾病国家国际科技合作基地//儿科学重庆市重点实验室,重庆 400014Laboratory of Stem Cell Biology and Therapy, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| |
Collapse
|